Literature DB >> 23558976

The influence of body mass index and low-grade systemic inflammation on thyroid hormone abnormalities in patients with type 2 diabetes.

Arnaldo Moura Neto1, Maria Candida Ribeiro Parisi, Marcos Antonio Tambascia, Sarah Monte Alegre, Elizabeth Joao Pavin, Denise Engelbrecht Zantut-Wittmann.   

Abstract

Previous reports highlight the role of systemic inflammation in the genesis of non-thyroidal illness syndrome and type 2 diabetes mellitus (T2DM). Our objective was to assess whether body mass index and the low-grade systemic inflammation would be associated with changes in thyroid hormone metabolism in patients with type 2 diabetes. This was a cross-sectional study of 104 subjects; 52 patients with type 2 diabetes and 52 in a control group, paired by age, gender and body mass index. We measured total (T) and free (F) thyroxine (T4) and triiodothyronine (T3), reverse T3 (rT3), the ratios FT3/rT3, FT3/FT4 and FT4/rT3, clinical parameters (age, gender, diabetes duration and complications, body mass index, waist circumference, hypertension, HbA1c), and high sensitivity C-reactive protein. Patients with DM presented lower levels of TT4 (p=0.006), TT3 (p<0.001) and FT3 (p<0.001) and higher of FT4 (p<0.001), waist circumference (p=0.047) and C-reactive protein (p<0.001). Body mass index was inversely correlated with FT4 (p=0.036) and TT3 (p=0.008). C-reactive protein was positively correlated with rT3 (p=0.001) and inversely with FT4/rT3 (p<0.001) and FT3/rT3 (p=0.014). Body mass index was an independent predictor for FT4 (B=-0.011, p=0.029) and TT3 levels (B=-1.118, p=0.003). Inflammation predicted the FT4/rT3 ratio (B=-0.190, p<0.001). C-reactive protein (B=0.235, p<0.001) and body mass index (B=-0.008, p=0.047) were independent predictors for rT3. In conclusion, type 2 diabetes was associated with a low T3 state. Body mass index and the low-grade systemic inflammation are related to the non-thyroidal illness syndrome in these patients, possibly by altering the activity of peripheral deiodinases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23558976     DOI: 10.1507/endocrj.ej13-0030

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  Nonthyroidal Illness Syndrome in Cardiac Illness Involves Elevated Concentrations of 3,5-Diiodothyronine and Correlates with Atrial Remodeling.

Authors:  Johannes W Dietrich; Patrick Müller; Fabian Schiedat; Markus Schlömicher; Justus Strauch; Apostolos Chatzitomaris; Harald H Klein; Andreas Mügge; Josef Köhrle; Eddy Rijntjes; Ina Lehmphul
Journal:  Eur Thyroid J       Date:  2015-05-23

2.  Relation of thyroid hormone abnormalities with subclinical inflammatory activity in patients with type 1 and type 2 diabetes mellitus.

Authors:  Arnaldo Moura Neto; Maria Candida Ribeiro Parisi; Sarah Monte Alegre; Elizabeth Joao Pavin; Marcos Antonio Tambascia; Denise Engelbrecht Zantut-Wittmann
Journal:  Endocrine       Date:  2015-06-07       Impact factor: 3.633

Review 3.  Abnormalities of Thyroid Hormone Metabolism during Systemic Illness: The Low T3 Syndrome in Different Clinical Settings.

Authors:  Arnaldo Moura Neto; Denise Engelbrecht Zantut-Wittmann
Journal:  Int J Endocrinol       Date:  2016-10-10       Impact factor: 3.257

4.  The impact of the metabolic phenotype on thyroid function in obesity.

Authors:  Paolo Marzullo; Chiara Mele; Stefania Mai; Gabriele Guzzaloni; Davide Soranna; Maria Antonella Tagliaferri; Maria Elisa Berselli; Flavia Prodam; Daniela Surico; Gianluca Aimaretti; Massimo Scacchi
Journal:  Diabetol Metab Syndr       Date:  2016-08-24       Impact factor: 3.320

5.  Non-Thyroidal Illness Syndrome in Patients Exposed to Indoor Air Dampness Microbiota Treated Successfully with Triiodothyronine.

Authors:  Taija Liisa Somppi
Journal:  Front Immunol       Date:  2017-08-07       Impact factor: 7.561

6.  Influence of Low Total Triiodothyronine Levels on Bone Turnover Markers in Type 2 Diabetes Mellitus.

Authors:  Zelin Li; Xian Yu; Luping Ren; Zi Wang; Fei Wang; Yujiao Jia; Shuchun Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-16       Impact factor: 3.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.